Abstract: The present invention provides a fermented honey product obtained by fermenting a honey-containing material having a honey concentration of more than 25% with Lactobacillus kunkeei.

Abstract: This invention relates to a process for preparing an inverse emulsion comprising mixing an aqueous solution comprising a water-soluble (co)polymer A synthesized from at least one cationic monomer and an inverse EMI 2 emulsion comprising a water-soluble (co)polymer B synthesized from at least one cationic monomer, optionally followed by distillation. This invention also relates to the inverse emulsion thus obtained, a detergent or cosmetic or softening composition comprising such an inverse emulsion, as well as the use of such an inverse emulsion to improve the softening properties of a fabric softening composition.

Abstract: The present invention is directed to novel compositions of rosemary extracts for use as a cat-deterrent formulation. The compositions of the present invention may be applied directly to an area, or object, to which it is desired to deter cats or animals from loitering or interaction. It is further contemplated that the compositions of the present invention may be applied directly to an area, or alternatively, be encapsulated in a container which substantially retains the solid components of the compositions of the present invention, but allows transport of the aromatic compounds.

Abstract: The invention relates to a nail varnish composition comprising: a) an embossed effect pigment comprising a metallic substrate in platelet form with embossed structure having a periodic pattern with diffractive elements, said substrate having been produced by PVD methods, and optionally at least one coating applied to the substrate, wherein the substrate has an elemental metal content of 80% to 100% by weight, based on the substrate, and wherein the effect pigment has been treated with a leafing additive for surface modification, b) at least one hydrocarbon resin as binder, c) at least one solvent or solvent mixture and d) optionally further auxiliaries. The invention further relates to a process for producing the nail varnish composition.

Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Abstract: The invention relates to a cosmetic composition in the form of an oil-in-water emulsion comprising: (i) at least one lipophilic surfactant with HLB less than or equal to 9, and (ii) at least one specific anionic surfactant comprising at least one sulfate and/or sulfonate function; said composition comprising from 0% to 8% by weight of additional surfactant(s) relative to the total weight of the composition. It also relates to the associated cosmetic process.

Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Abstract: An oral amphetamine extended release solid dose is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine—cation exchange resin complex—matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and/or the uncoated amphetamine—cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.

Abstract: An oil-in-water composition is provided. The composition includes an oil-in-water wherein the emulsion includes a) one or more antioxidants, b) one or more SPF boosters, c) one or more acrylate-based polymer capable of stabilizing the composition, d) one or more organic UV filters, e) one or more thickeners, f) one or more film formers; and g) one or more emulsifiers. The oil-in-water composition is provided in which the composition is essentially free of oxybenzone.

Abstract: The invention provides an antimicrobial personal cleansing composition comprising: (i) an aqueous continuous phase including one or more anionic cleansing surfactants; (ii) a dispersed phase including dispersed particles of zinc pyrithione (ZPT); (iii) a structuring polymer for the aqueous continuous phase which is selected from crosslinked alkali-swellable acrylic emulsion (ASE) polymers; and (iv) from 3 to 20 wt % niacinamide based on the total weight of the composition, wherein the structuring polymer is selected from crosslinked copolymers of (meth)acrylic acid with one or more C1 to C5 alkyl esters of (meth)acrylic acid.

Abstract: A method for reducing muscle contraction of a facial muscle or reducing the appearance of a fine line or wrinkle is disclosed. The method can include topical application of a composition to facial skin and/or to the fine line or wrinkle. The composition can include an effective amount of Rosmarinus officinalis leaf extract, an effective amount of Lavendula stoechas extract, and an effective amount of Acmella oleracea extract. Topical application of the composition to facial skin can reduce muscle contraction of the facial muscle. Topical application of the composition to the fine line or wrinkle can reduce the appearance of the fine line or wrinkle.

Abstract: The present application provides a radiation damage protecting agent comprising hydrogen gas as an active ingredient at a concentration of 18.5% by volume or less, for treating or alleviating, in a hyperbaric capsule under a pressure higher than standard atmospheric pressure, radiation damage in a human patient who has been exposed to radiation or who has received or receives radiotherapy, and a hyperbaric capsule for administering a hydrogen gas-containing therapeutic agent such as the radiation damage protecting agent to a patient including a human.

Abstract: An oil-in-water emulsion cosmetic containing (A) to (E) as essential components and having a pH of 6 or less: (A) an L-ascorbyl tetra fatty acid ester derivative represented by the following general formula (I) Formula 1 wherein R represents a branched alkyl fatty acid residue having 8 to 18 carbons; (B) a polar oil which is liquid at 25° C. and having an IOB value of 0.1 to 0.5; (C) a chelating agent; (D) an antioxidant; and (E) water.

Abstract: A water-in-oil emulsion cosmetic free of stickiness and oiliness, having semi-transparent or transparent appearance to effect feel of freshness, and able to provide moisturized feel is provided. The water-in-oil emulsion cosmetic contains (a) a solid moisturizer, (b) a polyether-modified silicone, and (c) a silicone oil having a refractive index in the range from 1.380 to 1.420 at 25° C., wherein a moisturizer content is 22 mass % or more relative to the total amount of the cosmetic.

Abstract: The present invention relates to cosmetic compositions having antioxidant properties and suitable for any type of skin.

Abstract: The invention pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the invention have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended release configuration.

Abstract: Compositions for topical application that effectively deliver antioxidants across the epidermis, dermis, or a combination thereof into cells and/or the bloodstream while concurrently maintaining chemical activity of the antioxidants. In certain aspects, these formulations include emulsions and balms each having a lipophilic carrier and a lipophilic antioxidant solubilized by the lipophilic carrier. Also disclosed herein are methods for making these compositions for topical application.

Abstract: This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.

Abstract: [Problem] An adhesion-preventing material having a high adhesion-preventing effect has been demanded. [Solution] An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.

Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.